Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMMART-PRIME: Individualized Therapy for Advanced Cancer
NCT03878524Phase 1Terminated
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Apr 2020
- Primary completion
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes, Irreversible Covalent Inhibitors, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abemaciclib, abiraterone, afatinib, bevacizumab, bicalutamide and 49 more in solid tumor (advanced stage) and hematological malignancies, sponsored by OHSU Knight Cancer Institute. Primary endpoint: Feasibility of implementing an individualized treatment strategy at 3 months. Started Apr 2020; status: terminated.
02
Drugs
abemaciclibabirateroneafatinibbevacizumabbicalutamide
03
Conditions
solid tumor (advanced stage)hematological malignancies
Beyond the preview
Go deeper on NCT03878524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03878524.